Conclusion: Both predicted 25(OH)D and total dietary vitamin D intake were not associated with endometrial cancer incidence. These results suggest that vitamin D may not protect against the development of endometrial cancer. However, the low and narrow vitamin D exposure range in the cohort may limit generalizability of the results.
introduction
There is substantial interest in the anticancer role of vitamin D, a nutrient traditionally associated with calcium metabolism. Vitamin D is synthesized following the skin's exposure to solar ultraviolet B (UVB) radiation, is found naturally in foods such as fish liver oil and fatty fish species, and is fortified in foods such as milk and cereal. Vitamin 2 D inhibits proliferation and promotes differentiation [1] [2] [3] . There is also epidemiological evidence, although not entirely consistent, supporting the protective role of vitamin D against the development of colorectal, breast, ovarian, prostate, and other cancers [4, 5] .
Endometrial cancer is the most common cancer of the female reproductive system and the fourth most common cancer in women [6] . Most endometrial cancers are adenocarcinomas that originate from the glandular epithelial tissue that line the endometrium. Risk factors for endometrial cancer include older age, family history, estrogen only hormone replacement therapy, obesity, nulliparity, early menarche, late menopause, diabetes, radiation therapy, and Tamoxifen [7] . Expression of the VDR and the enzyme involved in 1,25(OH) 2 D synthesis has been detected in human endometrial tissue [8] [9] [10] .
Few epidemiological studies have examined the potential effect of vitamin D on endometrial cancer, and there has been no prospective cohort analysis incorporating multiple vitamin D measures over time. An ecological study found an inverse association between UVB irradiance and endometrial cancer incidence [11] . Three hospital-based case-control studies examined the association between dietary vitamin D and endometrial cancer risk [12] [13] [14] , and a meta-analysis of these studies showed high between-study heterogeneity and an overall null association [15] . A recent pooled study using circulating 25(OH)D concentrations measured at a single time point found no association with endometrial cancer incidence [16] . This nested case-control study involved 830 cases and 992 controls from seven cohorts, and found no evidence of trend after adjusting for cohort, age, race, season at blood draw, and body mass index (BMI).
The main purpose of this analysis is to evaluate the association between vitamin D and endometrial cancer incidence by using predicted 25(OH)D updated biennially over 20 years of follow-up in the Nurses' Health Study (NHS). The 25(OH)D prediction method [17, 18] is used to estimate 25 (OH)D at multiple time points, using prospectively collected information on vitamin D determinants. This analysis also examines for the first time the associations between vitamin D-related single nucleotide polymorphisms (SNPs) and endometrial cancer, as well as the interaction between predicted vitamin D and these gene variants.
methods study population
The NHS is a prospective cohort study that began in 1976, when 121 700 female registered nurses aged 30-55 years and residing in 11 US states completed an initial questionnaire. Personal information such as lifestyle and dietary factors was subsequently updated every 2 or 4 years through questionnaire responses. From 1989-1990, blood was collected from 32 826 participants. About 97% of these blood samples arrived within 26 h of being drawn and were centrifuged and aliquotted into plasma, white blood cell, and red blood cell components.
For the cohort analysis, nurses who had hysterectomy, surgical menopause, or cancers other than nonmelanoma skin cancer were excluded at baseline (defined as 1986, the first year of predicted 25(OH)D derivation) and each subsequent follow-up cycle. There were 946 264 person-years of data involving 644 cases in the cohort analysis, covering the timeframe from 1986 to 2006.
For the nested case-control analysis, genotyping was carried out on 572 cases and their matched controls who were selected from the NHS cohort. Controls were randomly selected up to and including the questionnaire cycle in which the case was diagnosed. Matching factors for cases and controls include age, menopausal status, date, and postmenopausal hormone use at specimen collection, and fasting status at blood collection. 
questionnaire information
Questionnaire information was obtained from the follow-up cycles. Information on potential confounders was updated every 2 years when available. Updated BMI was calculated using height reported at baseline and weight reported at each cycle. Those missing weight in one cycle had their weight carried forward from the previous cycle, while those missing weight for two consecutive cycles were excluded from the analysis until they again reported their weight. Smoking was quantified using pack-years. Information on dietary sources of nutrients was obtained from a food frequency questionnaire (FFQ) that has been updated every 4 years since 1986. Dietary intake level was then calculated using the FFQ information as well as data from the US Department of Agriculture [19, 20] . Dietary sources include both natural food and dietary supplements. The cumulative average dietary intake level was used, adjusted for total energy intake.
SNP selection and genotyping
The 12 SNPs of interest were either selected from the VDR and vitamin D-binding protein (Gc) genes, or from a recent genome-wide association study (GWAS) meta-analysis on genetic predictors of circulating vitamin D levels [21] . VDR is on chromosome 12q13 and Gc is on chromosome 4q11-13. The selected VDR SNPs have been studied in relationship to various cancers other than that of the endometrium [22] . These VDR SNPs are Fok1 (rs2228570), Cdx2 (rs11568820), VDR-5132 (rs1989969), Bsm1 (rs1544410), Apa1 (rs7975232), Taq1 (rs731236), and Bgl1 (rs739837). SNPs on the Gc are rs4588 and rs7041. The remaining three SNPs from the GWAS meta-analysis are rs1790349, rs6599638, and rs2060793, which are, respectively, on the DHCR7, C10orf88, and CYP2R1 genes. The minor allele frequencies (MAF) range from 0.16 to 0.48. Genomic DNA was extracted from blood and buccal samples using the QIAmp (Qiagen, Chatsworth, CA) 96-spin blood protocol. Genotyping was carried out at the Dana Farber/Harvard Cancer Center High-Throughput Genotyping Core using the 5 0 nuclease assay (Taqman, Applied Biosystems, Foster City, CA).
Blinded quality control samples were inserted to validate genotyping procedures. Laboratory personnel were blinded to case-control status, and 5% blinded quality control samples were inserted to validate genotyping procedures; concordance for blinded samples was 100%. The amount of missing genotyping data was <4%.
statistical analyses
The Cox proportional hazards model was used in the cohort analysis. [23] .
The unconditional logistic regression model was used in the nested case-control analysis involving SNPs, and the study population was restricted to Caucasians. The additive genetic model was used, which assumes that the effect of the heterozygous genotype is intermediate between the two homozygous genotypes. The homozygous genotype of the reference allele was coded as 0. In the analysis of the association between vitamin D-related SNPs and endometrial cancer incidence, the matching factors age and menopausal status were adjusted in the model and the odds ratio (OR) was reported.
Analyses were done using the SAS Version 9.1 software (SAS Institute, Cary, NC). Quintiles were created using the rank procedure. Multiplicative interaction terms involving continuous variables were created to test for effect modification using the Wald test. All P values were two-sided.
results Table 1 shows the descriptive characteristics of the study population at baseline in 1986, the first year when the predicted 25(OH)D can be reasonably derived. Women with lower predicted 25(OH)D had fewer pack-years of smoking, fewer months of oral estrogen use, higher BMI, and lower calcium, folate, and retinol intake than women with higher predicted 25(OH)D.
For the multivariate analyses of Tables 2 and 3 After adequately adjusting for potential confounders, there was no significant dose-response between predicted 25(OH)D and endometrial cancer incidence ( p-trend = 0.33) ( Table 2 ). In the categorical analysis involving quintiles of predicted 25 (OH)D, there were also no significant associations with endometrial cancer incidence, with the HR for the highest (versus the lowest) quintile of predicted 25(OH)D as 1.00 (95% CI 0.73-1.36). Similar results were observed in continuous and categorical analyses involving total dietary vitamin D (Table 3) . Comparing the effect estimates obtained from Models 1 and 2 for Tables 2 and 3 (Table 4) .
There was no evidence of effect modification of the association between predicted 25(OH)D and endometrial cancer by total dietary folate, total dietary retinol, total dietary calcium, and smoking. In addition, none of the vitamin Drelated SNPs were significant effect modifiers of the predicted 25(OH)D and endometrial cancer association.
discussion
In this analysis, there was no association between vitamin D status and endometrial cancer incidence in the NHS study population. These findings are consistent with those from previous studies [15, 16] . This is the first study on endometrial cancer to use a prediction model for plasma 25(OH)D to quantify vitamin D [25, 26] , it is often measured only once per participant due to the cost and inconvenience of obtaining multiple blood samples. In addition, studies that examined the correlation of 25(OH)D levels over time [27, 28] showed that the correlation of the 25(OH)D levels decreases as the time between their measurements increases. The lower correlation over a longer period of time may be explained by relocation in residence to a place with a significantly different solar UVB radiation level, or by lifestyle changes that influence vitamin D exposure level, such as reducing outdoor activity or starting vitamin D supplement intake [29] . The prediction model incorporates the above factors as well as information on other lifestyle and dietary vitamin D determinants that is updated every 2 or 4 years using the NHS questionnaire. The frequent administration of questionnaires in the NHS makes it possible to predict 25(OH)D throughout the entire study follow-up, and these predicted levels collectively may be more indicative of long-term vitamin D status than plasma 25(OH)D measured at a single time point [18] . In addition to the above strength, the predicted 25(OH)D calculations are well-documented and have been applied to several studies [17, 30, 31] . Analyses of predicted and circulating 25(OH)D have already been done in separate studies for colorectal [30, 32] and pancreatic [31, 33] cancer. Therefore, this analysis using the predicted 25(OH)D complements the recently published pooled study involving circulating 25(OH)D and endometrial cancer incidence [16] . We also evaluated whether nutritional (folate, calcium, and retinol) and genetic factors (vitamin D-related SNPs) modified the association between vitamin D and endometrial cancer incidence, because of biological or epidemiological plausibility. There is biological evidence that the calcium and 1,25(OH) 2 D signaling pathways interact in the growth control of cancer cells [34] . Epidemiological studies have also shown that vitamin D and calcium may interact to influence cancer risk [35, 36] . Folate may play a role in the epigenetic regulation of vitamin D hydroxylase expression [37] . Retinol intake may compete for retinoid X receptors and antagonize the actions of vitamin D [38] , and an epidemiological study showed that high retinol intake countered the protective effect of vitamin D on distal colorectal adenoma risk [39] . Polymorphisms in genes for the VDR and other enzymes in the vitamin D activation pathway have been shown to modify the association between vitamin D and cancer risk [40] . None of these factors were found to be significant effect modifiers in this population; however, we had limited statistical power to detect interactions.
There are several limitations in this analysis. First, while the predicted 25(OH)D has potential advantages over a single blood measure, and incorporates multiple determinants of vitamin D status, there is still substantial unexplained variability in this exposure variable. For example, the UVB radiation exposure was assessed by an ecological variable that might not capture the individual exposure level. Therefore, in the 25(OH)D prediction model, we also included the physical activity variable, which is highly correlated with outdoor sun exposure. However, despite our effort to create a comprehensive prediction model, the predicted 25(OH)D measure may still be misclassified and consequently biased its association with endometrial cancer towards the null. Second, the plasma 25(OH)D outcome in the predicted 25(OH)D model may not reflect the endometrial tissue 25(OH)D level. Unfortunately, because it is impractical to sample tissues for 25 (OH)D measurements in healthy controls, this limitation is present in all cancer epidemiological studies using plasma 25 (OH)D. Third, the generalizability of the association between the predicted 25(OH)D and endometrial cancer incidence may be limited by the low and narrow range of vitamin D exposure. The majority of the women in the cohort had predicted 25 (OH)D under 30 ng/ml, and the range of the median values of the lowest and highest quintiles of predicted 25(OH)D was 8.1 ng/ml. The protective benefits of vitamin D against endometrial cancer may not manifest unless 25(OH)D levels are significantly higher than 30 ng/ml and the range of exposure is much wider. Finally, because genotyping is only done in a sample of women in the cohort, statistical power is reduced in analyses involving vitamin D-related SNPs.
In conclusion, this prospective cohort analysis of the NHS population suggests that there is no association between vitamin D and endometrial cancer either using long-term average predicted 25(OH)D or total dietary vitamin D alone. It will be interesting for future studies to examine whether vitamin D plays a role in endometrial cancer progression and survival. 
